Esperion Therapeutics, Inc.
ESPR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ESPR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ESPR
Esperion Therapeutics is a commercial-stage biopharmaceutical company focused on developing and marketing NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe) for LDL cholesterol lowering, with a pending merger expected to close in Q3 2026.
Key risk: Pending merger completion
BioSniper Score
Based on 6 of 6 signals
Market Cap
$819.5M
Cash Runway
26.7 moLead Asset
nexletol (Approved)Next Catalyst
Patent_Expiry · Jun 19, 2040Financial data as of Mar 31, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 2 catalysts · 2 FDA decisions for Esperion Therapeutics, Inc..
Esperion Therapeutics is a commercial-stage biopharmaceutical company focused on developing and marketing NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe) for LDL cholesterol lowering, with a pending merger expected to close in Q3 2026.
- FDA approved NEXLETOL and NEXLIZET in February 2020; commercial availability began in March and June 2020, respectively [sec_mda · as of 2026-05-08].
- Total revenue of $80.1M and net loss of -$25.2M for the period ended 2026-03-31 [sec].
- Cash and equivalents of $156.2M as of 2026-03-31 [sec].
- Shareholders' equity was -$302.0M as of 2026-03-31 [sec].
- A merger is expected to close in the third quarter of 2026 [sec_mda · as of 2026-05-08].
What works
- Commercial and market access is the top priority, weighted at 45% of 2025 corporate performance goals, focusing on exceeding U.S. net sales and improving 30-day fill rates [sec · filed 2026-04-16].
- The company estimates current cash resources, future product sales, and collaboration proceeds are sufficient to fund operations for the foreseeable future [sec_mda · as of 2026-05-08].
- Eligible for substantial additional sales and regulatory milestone payments and royalties under collaboration agreements with DSE, Otsuka, and DS [sec_mda · as of 2026-05-08].
What to weigh
- The company has incurred operating losses since inception and expects to continue incurring losses for the immediate future [sec_mda · as of 2025-11-06].
- Shareholders' equity was negative at -$302.0M as of 2026-03-31 [sec].
- Net cash used in operating activities was $13.1M for the year ended December 31, 2025 [sec_mda · as of 2026-03-10].
From the filings
Quoted directly from source documents.
FDA approval and commercial launch dates
“In February 2020, the FDA approved NEXLETOL and NEXLIZET. NEXLETOL was commercially available in the U.S. on March 30, 2020 and NEXLIZET was commercially available in the U.S. on June 4, 2020.”
SEC MD&A · May 8, 2026
Cash position as of year-end 2025
“31, 2025, our primary sources of liquidity were our cash and cash equivalents which totaled $167.9 million.”
SEC MD&A · March 10, 2026
Merger expected close in Q3 2026
“The Merger is expected to close in the third quarter of 2026.”
SEC MD&A · May 8, 2026
Commercial priority weighting
“Commercial and market access was the top priority of the company and weighted at 45%, centering on exceeding target U.S. net sales, improving 30‑day fill rates through payer and field execution, and expanding regional patient access to drive organic growth.”
SEC filings · April 16, 2026
Catalyst timeline
- 2040-06-19 · Patent_Expiry · NEXLETOL — Patent/Exclusivity Expiry: NEXLETOL — Patent/exclusivity protection for NEXLETOL expires, potentially allowing generic competition.
- 2040-06-19 · Patent_Expiry · NEXLIZET — Patent/Exclusivity Expiry: NEXLIZET — Patent/exclusivity protection for NEXLIZET expires, potentially allowing generic competition.
Risks & what to watch (3)›
Key risks
- Pending merger completion — The merger is subject to stockholder approval and other customary conditions; if it fails to close, the company's standalone prospects are uncertain [sec_mda · as of 2026-05-08].
- Negative shareholders' equity — Shareholders' equity was -$302.0M as of 2026-03-31, indicating accumulated deficits exceed assets [sec].
- Continued operating losses — The company expects to continue incurring operating losses for the immediate future, with net cash used in operations of $13.1M in 2025 [sec_mda · as of 2026-03-10].
What to watch
- Merger closing expected in Q3 2026 [sec_mda · as of 2026-05-08].
- Regulatory approvals for bempedoic acid in Israel (expected H1 2026) and Australia (expected Q4 2026) [sec_mda · as of 2025-11-06].
- Patent/exclusivity expiry for NEXLETOL and NEXLIZET on 2040-06-19 [upcoming catalysts].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Esperion Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Esperion Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
26.7 months
OCF -$28M · Net income -$25M
Lead: Approved
2 candidates
2 upcoming, next in ~5042d
0 buys · 6 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
206
Total value held
$503.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 20,867,520 | $57.2M |
| blackrock, inc. | 17,852,427 | $48.9M |
| wasatch advisors lp | 15,768,897 | $43.2M |
| two seas capital lp | 11,394,833 | $31.2M |
| orbimed advisors llc | 10,570,300 | $29.0M |
| two sigma investments, lp | 9,458,779 | $25.9M |
| marshall wace, llp | 7,075,083 | $19.4M |
| state street corp | 7,055,794 | $19.3M |
| d. e. shaw & co., inc. | 6,540,785 | $17.9M |
| geode capital management, llc | 5,955,739 | $16.3M |
Showing top 10 of 206 institutional holders of Esperion Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 13.0%
- Days to cover
- 5.9
- Shares short
- 33,129,776
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ESPR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Esperion Therapeutics, Inc.?
Esperion Therapeutics is a commercial-stage biopharmaceutical company focused on developing and marketing NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe) for LDL cholesterol lowering, with a pending merger expected to close in Q3 2026.
What is Esperion Therapeutics, Inc.'s lead drug candidate?
Esperion Therapeutics, Inc.'s most advanced tracked candidate is nexletol (Approved) for Reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with established CVD, or at high risk for a CVD event but without established CVD, and to reduce LDL-C in adults with primary hyperlipidemia..
What is Esperion Therapeutics, Inc.'s next catalyst?
Esperion Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: NEXLETOL" — expected June 19, 2040.
Who is the CEO of Esperion Therapeutics, Inc.?
Mr. Sheldon L. Koenig M.B.A. is the chief executive officer of Esperion Therapeutics, Inc. (ESPR).
Where is Esperion Therapeutics, Inc. headquartered?
Esperion Therapeutics, Inc. (ESPR) is headquartered in Ann Arbor, MI, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.